Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers
A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of ETI-204 in Healthy Subjects
연구 개요
상세 설명
Protocol AH-105 is a single center, randomized, double-blind, placebo-controlled, sequential, dose escalation study. It will evaluate the safety and PK of single IV doses of ETI-204 administered to approximately 108 healthy male and female subjects. At each dose level, 30 healthy subjects, including at least 4 females, will be randomly assigned to active drug, and at least 6 healthy subjects of both genders will be randomly assigned to matching placebo.
Description of Agent: ETI-204 is a monoclonal antibody (mAb) to protective antigen (PA) from Bacillus anthracis.
The study will consist of 3 phases: Screening, Inpatient, and Outpatient Follow-up. Enrollment criteria will be determined during the 21-day Screening Phase (Visit 1), following by a 3 night inpatient phase where eligible subjects will receive a single dose of IV ETI-204 or matching placebo as described above and undergo routine safety monitoring, dermatologic assessments, and blood draws at pre-specified time points. Subjects will be discharged from the center after collection of the 48-hour PK sample. During the subsequent 70-day outpatient follow-up phase, subjects will return to the center on Days 8, 15, 29, 43 and 71 for clinical laboratory testing (hematology and clinical chemistry), physical examinations and vital signs measurements, and routine safety monitoring. Blood samples for PK and anti-drug antibodies (ADA)will also be collected. The 70 day post-dosing follow-up in this study was selected to allow characterization for the PK profile of ETI-204 and the potential development of ADA.
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
Kansas
-
Overland Park, Kansas, 미국, 66211
- Quintiles
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria: Subjects who meet all of the criteria shown below may be included in the study.
- Healthy male or female subjects between 18 and 65 years of age.
- Subjects with a body mass index (BMI) > 18.5 and < 35 kg/m2.
- Female subjects of childbearing potential (not post-menopausal or surgically sterile) must have a negative urine β-hCG pregnancy test at Screening.
- Female subjects of childbearing potential (not post-menopausal or surgically sterile) must use a medically accepted method of contraception for the duration of the study, including the 70-day follow-up period. Acceptable methods of contraception include abstinence, a barrier method with spermicide, an intrauterine device (IUD) or a hormonal contraceptive (oral, transdermal, implanted, or injected) in conjunction with a barrier method.
- Male subjects must agree to practice abstinence or to use a condom with spermicide for the duration of the study, including the 70-day follow-up period.
- The subject has no clinically significant abnormalities on the clinical laboratory tests (hematology, clinical chemistry, or urinalysis) or ECG at Screening.
- Subject provides written informed consent.
Exclusion Criteria:Subjects who meet any of the criteria below will be excluded from participation in the study.
- Subject requires regular use of a medication for a chronic condition.
- Subject has a clinically significant comorbidity that would interfere with the completion of the study procedures or objectives, or would compromise the subject's safety.
- Subject has a systolic blood pressure (BP) > 140 mm Hg or a diastolic BP > 90 mm Hg.
- Subject has a systolic BP < 90 mm Hg.
- Subject has current suspected drug or alcohol abuse as specified in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) (American Psychiatric Association 2000).
- Subject has a positive alcohol or drug test result at Screening and on Day -1
- Subject has received an investigational agent within 30 days or 5 half-lives (whichever is longer) of Screening.
- Subject has congenital or acquired immunodeficiency syndrome.
- Subject has a positive test for Hepatitis B (surface antigen), Hepatitis C, or human immunodeficiency virus (HIV) at Screening.
- Subject smokes > 3 cigarettes per day.
- Subject has ever had prior treatment for anthrax exposure, prior anthrax infection, prior immunization with any anthrax vaccine or prior treatment with an investigational anthrax treatment
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: ETI-204
ETI-204, 앤팀
|
intravenously, single dose
다른 이름들:
|
|
가짜 비교기: 위약
|
intravenously, single dose
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Primary Objective
기간: 71 days
|
To evaluate the safety of increasing doses of ETI-204 in healthy subjects
|
71 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Secondary Objective
기간: 71 days
|
To evaluate the PK of increasing singles doses of ETI-204 in healthy subjects. To evaluate the immunogenicity of ETI-204 following IV administration in healthy subjects. |
71 days
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Eleanor A Lisbon, M.D., M.P.H, Quintiles Phase One Services
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- AH105
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
ETI-204, "Anthim"에 대한 임상 시험
-
University of Aarhus모병낭포성 섬유증(CF) | CFTR 유전자 돌연변이덴마크
-
ACADIA Pharmaceuticals Inc.초대로 등록
-
Guangzhou Women and Children's Medical Center아직 모집하지 않음
-
ACADIA Pharmaceuticals Inc.초대로 등록알츠하이머병 정신병프랑스, 불가리아, 미국, 체코, 세르비아, 스페인, 칠레, 이탈리아, 브라질, 대만, 멕시코, 대한민국
-
Wyeth is now a wholly owned subsidiary of Pfizer완전한
-
First Affiliated Hospital of Guangxi Medical University아직 모집하지 않음
-
Wyeth is now a wholly owned subsidiary of Pfizer종료됨진성 당뇨병중국, 미국, 캐나다, 멕시코, 러시아 연방, 크로아티아, 영국, 아르헨티나, 호주, 인도, 남아프리카, 그리스, 우크라이나, 루마니아, 이탈리아, 홍콩, 이전 세르비아 몬테네그로, 브라질